

# HER2Negative Metastatic Breast Cancer - Epidemiology Forecast to 2032

<https://marketpublishers.com/r/H4F8D7C8CB6EEN.html>

Date: January 2022

Pages: 60

Price: US\$ 3,950.00 (Single User License)

ID: H4F8D7C8CB6EEN

## Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'HER2Negative Metastatic Breast Cancer - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted HER2Negative Metastatic Breast Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

### Geographies Covered

The United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2019-2032

### HER2Negative Metastatic Breast Cancer Understanding

The DelveInsight HER2Negative Metastatic Breast Cancer epidemiology report gives a thorough understanding of the HER2Negative Metastatic Breast Cancer by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for HER2Negative Metastatic Breast Cancer in the US, Europe, and Japan. The report covers the detailed information of the HER2Negative Metastatic Breast Cancer epidemiology scenario in

seven major countries (US, EU5, and Japan).

## HER2Negative Metastatic Breast Cancer Epidemiology Perspective by DelveInsight

The HER2Negative Metastatic Breast Cancer epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The HER2Negative Metastatic Breast Cancer epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The HER2Negative Metastatic Breast Cancer epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

## HER2Negative Metastatic Breast Cancer Detailed Epidemiology Segmentation

The HER2Negative Metastatic Breast Cancer epidemiology covered in the report provides historical as well as forecasted HER2Negative Metastatic Breast Cancer epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight HER2Negative Metastatic Breast Cancer report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

## Scope of the Report

The HER2Negative Metastatic Breast Cancer report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

The HER2Negative Metastatic Breast Cancer Epidemiology Report and Model provide an overview of the global trends of HER2Negative Metastatic Breast Cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)

The report provides insight into the historical and forecasted patient pool of

HER2Negative Metastatic Breast Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan

The report helps recognize the growth opportunities in the 7MM for the patient population

The report assesses the disease risk and burden and highlights the unmet needs of HER2Negative Metastatic Breast Cancer

The report provides the segmentation of the HER2Negative Metastatic Breast Cancer epidemiology

## Report Highlights

11-year Forecast of HER2Negative Metastatic Breast Cancer epidemiology

7MM Coverage

Prevalent and Diagnosed Cases of HER2Negative Metastatic Breast Cancer

Cases of HER2Negative Metastatic Breast Cancer by Mutation Types

HER2Negative Metastatic Breast Cancer Cases associated with Clinical Manifestations

## KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

## Key Questions Answered

What will be the growth opportunities in the 7MM with respect to the patient population pertaining to HER2Negative Metastatic Breast Cancer?

What are the key findings pertaining to the HER2Negative Metastatic Breast Cancer epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?

What would be the total number of patients of HER2Negative Metastatic Breast Cancer across the 7MM during the forecast period (2019-2032)?

Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?

At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

What is the disease risk, burden and unmet needs of HER2Negative Metastatic Breast Cancer?

What are the currently available treatments of HER2Negative Metastatic Breast Cancer?

## Reasons to buy

The HER2Negative Metastatic Breast Cancer Epidemiology report will allow the user to

-

Develop business strategies by understanding the trends shaping and driving the global HER2Negative Metastatic Breast Cancer market

Quantify patient populations in the global HER2Negative Metastatic Breast Cancer market to improve product design, pricing, and launch plans

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HER2Negative Metastatic Breast Cancer therapeutics in each of the markets covered

Understand the magnitude of HER2Negative Metastatic Breast Cancer population by its epidemiology

The HER2Negative Metastatic Breast Cancer Epidemiology Model developed by

DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

## Key Assessments

Patient Segmentation

Disease Risk & Burden

Risk of disease by the segmentation

Factors driving growth in a specific patient population

## Contents

### 1. KEY INSIGHTS

### 2. EXECUTIVE SUMMARY OF HER2NEGATIVE METASTATIC BREAST CANCER

### 3. HER2NEGATIVE METASTATIC BREAST CANCER: DISEASE BACKGROUND AND OVERVIEW

#### 3.1. Introduction

#### 3.2. Sign and Symptoms

#### 3.3. Pathophysiology

#### 3.4. Risk Factors

#### 3.5. Diagnosis

### 4. PATIENT JOURNEY

### 5. EPIDEMIOLOGY AND PATIENT POPULATION

#### 5.1. Epidemiology Key Findings

#### 5.2. Assumptions and Rationale: 7MM

#### 5.3. Epidemiology Scenario: 7MM

##### 5.3.1. HER2Negative Metastatic Breast Cancer Epidemiology Scenario in the 7MM (2019- 2032)

#### 5.4. United States Epidemiology

##### 5.4.1. HER2Negative Metastatic Breast Cancer Epidemiology Scenario in the United States (2019- 2032)

#### 5.5. EU-5 Country-wise Epidemiology

##### 5.5.1. Germany Epidemiology

###### 5.5.1.1. HER2Negative Metastatic Breast Cancer Epidemiology Scenario in Germany (2019- 2032)

##### 5.5.2. France Epidemiology

###### 5.5.2.1. HER2Negative Metastatic Breast Cancer Epidemiology Scenario in France (2019- 2032)

##### 5.5.3. Italy Epidemiology

###### 5.5.3.1. HER2Negative Metastatic Breast Cancer Epidemiology Scenario in Italy (2019- 2032)

##### 5.5.4. Spain Epidemiology

###### 5.5.4.1. HER2Negative Metastatic Breast Cancer Epidemiology Scenario in Spain

(2019- 2032)

5.5.5. United Kingdom Epidemiology

5.5.5.1. HER2Negative Metastatic Breast Cancer Epidemiology Scenario in the United Kingdom (2019-2032)

5.6. Japan Epidemiology

5.6.1. HER2Negative Metastatic Breast Cancer Epidemiology Scenario in Japan (2019- 2032)

## **6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES**

6.1. HER2Negative Metastatic Breast Cancer Treatment and Management

6.2. HER2Negative Metastatic Breast Cancer Treatment Algorithm

## **7. KOL VIEWS**

## **8. UNMET NEEDS**

## **9. APPENDIX**

9.1. Bibliography

9.2. Report Methodology

## **10. DELVEINSIGHT CAPABILITIES**

## **11. DISCLAIMER**

## **12. ABOUT DELVEINSIGHT**

\*The table of contents is not exhaustive; will be provided in the final report

## List Of Tables

### LIST OF TABLES

List of Table:

Table 1: HER2Negative Metastatic Breast Cancer Epidemiology in 7MM (2019-2032)

Table 2: HER2Negative Metastatic Breast Cancer Diagnosed and Treatable Cases in 7MM (2019-2032)

Table 3: HER2Negative Metastatic Breast Cancer Epidemiology in the United States (2019-2032)

Table 4: HER2Negative Metastatic Breast Cancer Diagnosed and Treatable Cases in the United States (2019-2032)

Table 5: HER2Negative Metastatic Breast Cancer Epidemiology in Germany (2019-2032)

Table 6: HER2Negative Metastatic Breast Cancer Diagnosed and Treatable Cases in Germany (2019-2032)

Table 7: HER2Negative Metastatic Breast Cancer Epidemiology in France (2019-2032)

Table 8: HER2Negative Metastatic Breast Cancer Diagnosed and Treatable Cases in France (2019-2032)

Table 9: HER2Negative Metastatic Breast Cancer Epidemiology in Italy (2019-2032)

Table 10: HER2Negative Metastatic Breast Cancer Diagnosed and Treatable Cases in Italy (2019-2032)

Table 11: HER2Negative Metastatic Breast Cancer Epidemiology in Spain (2019-2032)

Table 12: HER2Negative Metastatic Breast Cancer Diagnosed and Treatable Cases in Spain (2019-2032)

Table 13: HER2Negative Metastatic Breast Cancer Epidemiology in the United Kingdom (2019-2032)

Table 14: HER2Negative Metastatic Breast Cancer Diagnosed and Treatable Cases in the United Kingdom (2019-2032)

Table 15: HER2Negative Metastatic Breast Cancer Epidemiology in Japan (2019-2032)

Table 16: HER2Negative Metastatic Breast Cancer Diagnosed and Treatable Cases in Japan (2019-2032)



## List Of Figures

### LIST OF FIGURES

#### List of Figures

Figure 1 HER2Negative Metastatic Breast Cancer Epidemiology in 7MM (2019-2032)

Figure 2 HER2Negative Metastatic Breast Cancer Diagnosed and Treatable Cases in 7MM (2019-2032)

Figure 3 HER2Negative Metastatic Breast Cancer Epidemiology in the United States (2019-2032)

Figure 4 HER2Negative Metastatic Breast Cancer Diagnosed and Treatable Cases in the United States (2019-2032)

Figure 5 HER2Negative Metastatic Breast Cancer Epidemiology in Germany (2019-2032)

Figure 6 HER2Negative Metastatic Breast Cancer Diagnosed and Treatable Cases in Germany (2019-2032)

Figure 7 HER2Negative Metastatic Breast Cancer Epidemiology in France (2019-2032)

Figure 8 HER2Negative Metastatic Breast Cancer Diagnosed and Treatable Cases in France (2019-2032)

Figure 9 HER2Negative Metastatic Breast Cancer Epidemiology in Italy (2019-2032)

Figure 10 HER2Negative Metastatic Breast Cancer Diagnosed and Treatable Cases in Italy (2019-2032)

Figure 11 HER2Negative Metastatic Breast Cancer Epidemiology in Spain (2019-2032)

Figure 12 HER2Negative Metastatic Breast Cancer Diagnosed and Treatable Cases in Spain (2019-2032)

Figure 13 HER2Negative Metastatic Breast Cancer Epidemiology in the United Kingdom (2019-2032)

Figure 14 HER2Negative Metastatic Breast Cancer Diagnosed and Treatable Cases in the United Kingdom (2019-2032)

Figure 15 HER2Negative Metastatic Breast Cancer Epidemiology in Japan (2019-2032)

Figure 16 HER2Negative Metastatic Breast Cancer Diagnosed and Treatable Cases in Japan (2019-2032)

\*The table of contents is not exhaustive; will be provided in the final report

## I would like to order

Product name: HER2Negative Metastatic Breast Cancer - Epidemiology Forecast to 2032

Product link: <https://marketpublishers.com/r/H4F8D7C8CB6EEN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H4F8D7C8CB6EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970